New England Biolabs expands PCR reagents product line
New England Biolabs, a privately held company that offers recombinant and native enzymes for genomic research, has expanded its line of PCR reagents to include OneTaq and OneTaq Hot Start DNA Polymerases.
Aoxing Pharmaceutical has reported $1,940,539 revenues for the three months ended 31 December 2010 or second quarter of fiscal year 2011, a 24.7% increase over the revenues of $1,556,431 realized during the three months ended 31 December 2009.
Apricus Bio licenses ED drug Vitaros rights to Neopharm in Israel
San Diego-based Apricus Biosciences has granted Israel-based Neopharm Group the exclusive rights to market and sell erectile dysfunction (ED) treatment Vitaros and, when and if available, its formulation for the treatment of premature ejaculation (PE), in Israel and the Palestinian Territories of the Gaza Strip and the West Bank.
BioTime agrees to acquire Glycosan BioSystems
BioTime has signed a definitive agreement to merge Utah-based Glycosan BioSystems with BioTime’s wholly-owned subsidiary, OrthoCyte.
ADVENTRX inks agreement to acquire SynthRx
ADVENTRX Pharmaceuticals, a specialty pharmaceutical company developing therapeutics for cancer treatment, has entered into an agreement to acquire SynthR, a private biotechnology company developing a purified form of a rheologic and antithrombotic agent, poloxamer 188 (188), indicated as a treatment for micro-vascular disorders.
Sinclair, IS Pharma in talks to form pan-European specialty pharma company
Sinclair Pharma and IS Pharma are engaged in talks about a possible merger of the two companies to create a fully integrated pan-European specialty pharmaceutical company Sinclair IS Pharma.
Perrigo settles Rogaine foam patent litigation
Perrigo, a developer, manufacturer and distributor of OTC and generic prescription pharmaceuticals, infant formulas, nutritional products, APIs and pharmaceutical and medical diagnostics, has agreed to settle its Hatch-Waxman litigation related to the Rogaine (Minoxidil) foam brought by Stiefel Research Australia, a GSK company.
Medivir, Janssen collaborate to combat dengue virus infection
Medivir, an emerging Swedish research-based specialty pharmaceutical company focused on treating infectious diseases, has signed a collaboration agreement with Janssen Pharmaceutica to discover and develop drugs for the prophylaxis and treatment of dengue virus infection.
Special thanks to www.IndianPharmacy.org an indian pharmacy who provides me the list of generic drugs and data. Indian Pharmacy online supplies quality generic drugs, free prescription and she can ship the good worldwide.
Related posts:
